You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Diabetes and other endocrinal, nutritional and metabolic conditions
  5. Diabetes

Dapagliflozin in combination therapy for treating type 2 diabetes

  • Technology appraisal guidance
  • Reference number: TA288
  • Published:  26 June 2013
  • Last updated:  23 November 2016
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History
Download guidance (PDF)
  • Overview
  • 1 Recommendations
  • 2 The technology
  • 3 The manufacturers' submission
  • 4 Consideration of the evidence
  • 5 Implementation
  • 6 Recommendations for further research
  • 7 Appraisal Committee members and NICE project team
  • 8 Sources of evidence considered by the Committee
  • Update information

Update information

November 2016: Recommendation 1.3 has been amended in response to the publication of NICE's technology appraisal guidance on dapagliflozin in triple therapy for treating type 2 diabetes.

December 2015: Recommendation 1.1 and the related NICE guidance section have been amended in response to the publication of the updated NICE guideline CG87 on type 2 diabetes in adults (now replaced by NICE's guideline on type 2 diabetes in adults).

ISBN: 978-1-4731-0194-4


Previous page 8 Sources of evidence considered by the Committee
Back to top